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Abstract
Background: Neoplasms of the oral maxillofacial area are an interesting entity characterized by
differences in nomenclature and classification at different centers.
We report neoplastic histopathological diagnoses seen at the departments of oral maxillofacial
surgery of Muhimbili and Mulago referral hospitals in Tanzania and Uganda respectively over a 10-
year period.
Methods: We retrieved histopathological reports archived at the departments of oral maxillofacial
surgery of Muhimbili and Mulago referral hospitals in Tanzania and Uganda respectively over a 10-
year period from June 1989–July 1999.
Results: In the period between June 1989 and July 1999, 565 and 1298 neoplastic oro-facial cases
were retrieved of which 284 (50.53%) and 967 (74.54%) were malignant neoplasms at Muhimbili
and Mulago hospitals respectively. Overall 67.28% of the diagnoses recorded were malignant with
Kaposi's sarcoma (21.98%), Burkiits lymphoma (20.45%), and squamous cell carcinoma (15.22%)
dominating that group while ameloblastoma (9.23%), fibromas (7.3%) and pleomorphic adenoma
(4.95%) dominated the benign group.
The high frequency of malignancies could be due to inclusion criteria and the clinical practice of
selective histopathology investigation. However, it may also be due to higher chances of referrals
in case of malignancies.
Conclusion: There is need to reexamine the slides in these two centers in order to bring them
in line with the most recent WHO classification so as to allow for comparison with reports from
else where.
Background
Neoplasms of the oral maxillofacial area are a source of
great differences in nomenclature and classification mak-
ing comparison from different countries difficult. Reports
from different parts of the world show differences in the
pattern of maxillofacial tumors seen. [1-5] A couple of
authors have revisited the histopathological slides of cer-
tain groups of maxillofacial tumors in their centers with
the aim of reclassifying the diagnoses made at the time to
bring them in line with the current WHO classification.
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[6,7] This is meant to bring sanity in the body of research
and clinical records. Uganda at the moment has only one
serving oral pathologist and Tanzania is no better, hence
reliance on already over-stretched general pathologists to
do the oral histopathological diagnosis. The burden of
tropical infectious diseases such as malaria, tuberculosis
and HIV/AIDS relegates oro-facial diseases to the bottom
of the priority list by both government and donor agen-
cies.
Although some work has been reported on these neo-
plasms from East Africa, most was done years back and
the numbers reported were few.
In 1956, Pritam and Cook reported sarcomas, adamanti-
noma and carcinomas as the commonest oral maxillofa-
cial neoplasms in Uganda. [8] Four years later Dodge
reported an unusually high incidence of odontogenic
tumors in Ugandan Africans. [9] However, when Slavin
and Cameron reported on ameloblastoma from both
Uganda and Tanzania they attributed the high numbers to
a harvesting period. [10] Recently Simon et al reported
that some of the tumors that were initially thought to have
a racial preponderance for African blacks are in fact equal
in incidence with other parts of the world. [11] Although
Wakiaga J.M et al in a report from Kenya had high number
of cases, they restricted inclusion to cases of jaw tumors
only. Ameloblastoma, Burkitts lymphoma, ossifying
fibroma and osteogenic sarcoma were reported as being
the commonest in that order. [12]
We felt that an update on the different histopathological
entities reported and recorded at the oral maxillofacial
surgery departments in East Africa was long overdue. We
hope it will show the huge discrepancies in classification
with the standing WHO classification and as a result gen-
erate interest and funding so as to streamline our records.
Methods
Mulago Hospital and Muhimbili National Referral Hospi-
tal are the two biggest referral hospitals for Uganda and
Tanzania respectively. They were the main treatment cent-
ers for oral maxillofacial neoplasms until recently when
some other regional referral centers in Tanzania got the
personnel to man the departments. They both house the
national cancer registry at the departments of human
pathology and morbid anatomy. The normal procedure is
that the histopathological results are filed at both the rel-
evant departments as well as the department of human
pathology and morbid anatomy.
The data presented here was obtained from the biopsy
results files in the departments of oral maxillofacial sur-
gery and oral pathology at both hospitals stretching from
June 1989 to July 1999. The choice of the time interval
was due to the fact that from the year 2000 some regional
referral hospitals in Tanzania had set up oral and maxillo-
facial surgery departments hence reducing the catchment
area for Muhimbili hospital. The tumor type, age, sex and
site of lesions were recorded in a pre-designed data collec-
tion form. During data collection, the diagnoses were
recorded as reported on the biopsy result slips. However,
"unspecified" such as undetermined malignancies and
those that gave histological characteristics but no final
diagnoses were excluded from the study during analysis.
Reports of fine needle aspiration cytology and microscopy
of blood or fluid smears were excluded. Repeat biopsies
were counted once with the later diagnosis taken. This was
in light of the fact that at both centers the previous biopsy
number is recorded when a repeat is done allowing the
pathologists to review the old slide alongside the repeat
slide enabling a more informed decision. Those repeat
biopsies that were done due to recurrence after treatment
were recorded once except if the second time around a dif-
ferent diagnosis was given. Non neoplastic cysts, dysplas-
tic and inflammatory lesions were excluded from the
study.
An interval of 10 years was used to classify the data into
age groups. As for those that were not specified or
recorded as adult, they were categorized as unknown
while the ones recorded as child were placed under the 10
years and below.
The site of the neoplasm was taken as recorded on the
slips. However, those cases appearing adjacent to major
salivary glands should be taken with caution. The lip
included both lower and upper while the palate repre-
sented hard and soft palate. Site recorded as oral cavity the
neoplasm involved the tongue (oral and oropharygeal
parts), floor of the mouth, gingival and buccal mucosa.
Statistical analysis including student's t tests and simple
proportion tests done using excel Microsoft office 2003.
Results
In the period between June 1989 and July 1999, 565 and
1298 neoplastic oro-facial cases were retrieved of which
284 (50.53%) and 967 (74.54%) were malignant neo-
plasms at Muhimbili and Mulago hospitals respectively.
In Tanzania (Muhimbili hospital), squamous cell carci-
noma (32.75%) was the commonest in the malignant cat-
egory followed by Burkitts lymphoma (32.40%) and
Kaposis sarcoma (15.14%). Only one case of malignant
odontogenic neoplasm (malignant ameloblastoma) was
reported.
On the other hand, in Uganda (Mulago hospital), Kaposis
sarcoma(37.78%) was the commonest malignant neo-
plasm followed by Burkitts lymphoma (30,12%)thenBMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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squamous cell carcinoma (19.67%). Combined data (i.e
Muhimbili plus Mulago), malignant neoplasms were
67.28% of all retrieved results with Kaposis sarcoma
(32.64%), Burkitts lymphoma (30.56%) and squamous
cell carcinoma (22.64%) dominating.
As for the benign neoplasms, ameloblastoma (35.61%),
pleomorphic adenoma (17.63%) and fibromas (17.57%)
were the most frequent in Tanzania while in Uganda it
was fibromas (26.67%), ameloblastoma (22.12%), pleo-
morphic adenoma (13.03%) and papilloma (10.6%). The
different diagnoses seen at the two hospitals are shown in
Table 1. Overall, odontogenic neoplasms were 11.73%,
9.8% (Uganda) 15.30% (Tanzania).
The gender distribution of the different neoplasms is as
shown in Table 2. Of the retrieved cases 53.71% were
males compared to 45.32% females and 0.97% were not
specified. The over all the male female ratio was 1.2:1,
1.3:1 in Tanzania compared to 1.14:1 in Uganda. Of the
male cases 71.74% were malignant compared to 61.88%
among females.11.12% of the male neoplasms were
odontogenic compared to 21.65% of the female cases.
Age distribution of the different diagnosis is shown in
table 3. The overall average age was 29.29 ± 19.72 with a
range of 0.06–97 years. The neoplasms showed a wide
range of age distribution with most neoplasms peaking in
the second and third decade except Burkitts lymphoma
that peaked below 10 years (Figure 1). Squamous cell car-
cinoma peaked in the sixth decade and dominated malig-
nancies in the sixth decade upwards.
The site distribution of some selected neoplasms is as
summarized in table 4. The neoplasms had different site
predilections. For instance 55.72% of neoplasms whose
site was recorded as the mandible were ameloblastoma
while 56.4% of the palatal cases were Kaposi's sarcoma.
Unfortunately, in over 50% of all the slips, the site of
biopsy wasn't recorded.
Discussion
In this study, malignant maxillofacial neoplasms
accounted for up to 67.28% a figure that is very high com-
pared to other reports. [1,3,5] However, the other reports
included cysts, granulomas and inflammatory conditions
and thus malignancies expressed as a percentage of all the
biopsies were bound to be lower. A high frequency of
malignancies has been reported by some African studies
such as Chidzonga et al and Aregbesola et al compared to
Asian, American or European reports. [2-5,13] This could
be due to differences in clinical practice whereby in some
centers all surgical specimens are sent out for histological
investigations, while in others radiographic and clinical
features are used as criteria for what needs histopatholog-
ical investigation. In our study, the exclusion of non neo-
plastic cysts, hyperplastic and inflammatory lesions
combined with the clinical practice of selective histologi-
cal investigations and high likelihood of referral in case of
malignancy, may explain the high frequency of malignan-
cies reported. We decided to leave out the inflammatory
and hyperplastic lesions since in many instances they are
recorded as no cancer seen which made it difficult to
include them in the study. Final diagnosis such as no can-
cer seen may be due to reliance on already over-stretched
general pathologists to diagnose oral pathological slides.
Tay et al encountered a similar problem when it came to
oral histology reports from general pathologists. [3] The
commonest malignancy in these series was Kaposi's sar-
coma (21.98%) a neoplasm not reported by Tay et al,
Krutchkoff et al, Ogunbodede et al. [3,13,14] Jones et al
reported KS lesion (0.3%) at a UK center but the percent-
age was low compared to our study. [5] This may be due
to the fact that KS biopsies are obtained from the skin in
other centers. On the other hand Mbulaiteye SM et al
reported an increased standardized incidence risk for KS
among HIV infected persons of 6.4 (95% CI 4.8–8.4) and
therefore many of these biopsies are likely to have been
from HIV infected individuals. Additionally Goedert et al
earlier on reported a 310 fold increase in risk of acquiring
KS following HIV infection while Ziegler et al reported a
40 fold increment with the oro-facial dominant pattern
accounting for up to 79% of the cases in Uganda. [15-17]
In this study Uganda contributed the bulk of Kaposi's sar-
coma cases as shown in table 1, hence Ziegler et al's report
may be a good explanation for this unusually high fre-
quency of KS in our series. However, it is worth noting
that this is highly speculative since we don't have the HIV
status of the cases diagnosed with Kaposi's sarcoma. Pres-
ently the picture may be different given the increased
availability of highly active antiretroviral therapy (HART),
which have been reported to decrease the prevalence of
some AIDS-associated oral facial conditions. [18,19]A
recent study in Tanzania noted a very low prevalence of
Kaposi's sarcoma among patients on HART. [20] It would
be interesting to do research on the trend of Kaposi's sar-
coma with the advent of HART versus the period prior.
There was equal sex distribution of KS (Table 2), suggest-
ing that the exposure to risk factors is equal. The majority
of the KS cases (69.68%) were in the 3rd and 4th decade
(Table 3). This tallies with the HIV AIDS prevalence that is
highest in the 3rd and 4th decades. [21,22] The palate and
tongue were the commonest sites for KS lesions (47.55%,
26.47% respectively) however, more than half of the
biopsy reports, the site was not specified. The gender dis-
tribution of 1:1 was similar to that reported by earlier
studies. [15,16]
The second commonest malignancy overall was Burkitts
lymphoma (20.54%). However, in Tanzania, Burkitt'sBMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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Table 1: Distribution of oralfacial neoplasms in Mulago Uganda (UG) and Muhimbili Tanzania (TZ)
Diagnosis Abbreviation UG TZ % of overall
Ameloblastoma AME 73 99 9.23
Odontogenic myxoma MYX 6 15 1.13
Ameloblastic fibroma AMEF 1 3 0.21
Adenomatoid odontogenic tumour AOT 1 1 0.11
Odontoma ODT 1 0 0.05
Odontogenic fibroma ODF 0 5 0.27
Malignant ameloblastoma MAME 0 1 0.05
Fibroma FIB 88 48 7.30
Ossifying fibroma OF 0 2 0.11
Cementifying fibroma CF 4 5 0.48
Chondroma CHD 1 2 0.16
Osteoma OST 5 4 0.48
Osteo sarcoma OSS 2 5 0.38
Fibro sarcoma FIS 4 1 0.27
Chondrosarcoma/Chondro myxoid fibro sarcoma CHS 7 1 0.43
Myxoid sarcoma MYXS 1 0 0.05
Round cell carcinoma RCS 0 1 0.05
Burkitts lymphoma BUR 291 91 20.54
Non Hodgkin's lymphoma NHL 11 6 0.91
Histiocytic lymphoma HLH 1 0 0.05
Centroblastic polymorphic lymphoma CPL 0 1 0.05
Squamous cell carcinoma SCCa 190 93 15.22
Anaplastic carcinoma ACa 9 8 0.86
Un/Poorly differentiated carcinoma UCa 19 0 1.02
Nasopharyngeal carcinoma NPCa 1 0 0.05
Non keratinizing carcinoma of tonsil NKTca 0 1 0.05
Verrucous carcinoma Vca 3 3 0.32
Bassal cell carcinoma BCCa 0 1 0.05
Adenoma ADN 16 3 1.02
Pleomorphic adenoma PLA 43 49 4.95
Monomorphic adenoma MOA 0 1 0.05
Oxyphill cell adenoma OCA 3 0 0.16
Adeno carcinoma ADCa 22 10 1.72
Adenocystic carcinoma (Cylindroma) ACCa 14 5 1.02
Salivary gland carcinoma SGCa 2 1 0.16
Mucous secreting carcinoma MSCa 4 0 0.22
Muco epidermoid carcinoma MECa 5 4 0.48
Carcinoma ex pleomorphic adenoma CaPLA 1 0 0.05
Haemagio pericytoma HAP 2 2 0.22
Kaposis sarcoma KS 365 44 21.98
Haemagio sarcoma HAS 0 1 0.05
Granular cell myoblastoma GCM 6 0 0.32
Leiomyoma LEI 0 1 0.05
Rhabdomyosarcoma RHS 8 1 0.48
Lymphagioma LPH 11 1 0.65
Lymphagiosarcoma LPHS 0 1 0.05
Lipoma LIP 19 10 1.56
Liposarcoma LIS 1 1 0.11
Melanotic prognoma MEP 1 0 0.05
Melanoma MEL 5 2 0.38BMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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lymphoma came in third after squamous cell carcinoma
(Table 1). Burkitt's lymphoma has been consistently
reported at high frequencies in African series but not
Asian and American series. [3,4,12,23,24] This has lead to
speculations as to why such a high frequency occurs in
Africa. The various reasons advanced include geographi-
cal, HIV/AIDS, socio economic factors, nutrition, viral
infections and genetic. [14,16,25,26] In our study it's hard
to explain the high frequency hence more studies are
required to investigate whether the improving situation in
African countries is showing reduction in this tumor to
levels close to those seen in other parts of the world. A
recent study from Kenya reported geographical differences
in clinical features of Burkitt's lymphoma. The coastal,
western and central regions had facial swelling as the pre-
senting complaint in 81%, 64% and 31% respectively.
[27] Such a phenomenon could lead to a high number of
Burkitts lymphomas in oral facial biopsies in some centers
compared to others and may as well explain the huge
numbers in Uganda compared to Tanzania and absence of
Burkitt's lymphoma in some studies from Africa. The gen-
der distribution was similar to other reports from Nigeria
and Kenya with boys being more affected than girls (table
2). [4,12,27] The mean age at diagnosis was 7.21 ± 0.513
years with a range of 2–45 (table 3). It is worth noting that
in this study 89.3% were under the age of 10 and 9.2%
between 10 and 20 years. The frequency distribution of
those below 10 is as shown in figure 1. These findings
agree with other reports from other parts of
Africa.[4,12,24] The site of Burkitt's lymphoma was
recorded in only77 cases (mandible 65%, the jaws i.e.
both maxilla and mandible accounted 9.1% and maxilla
14.9%). Although very few cases had the site recorded, the
results are in agreement with already published reports.
[4,12] There were 17 cases reported as non Hodgkin's
lymphoma of which only two were below 10 years and 8
over 40 years. These could have been any other types of
non hodgkins lymphoma such as large cell lymphoma.
Jones et al [5] had non Hodgkin's lymphoma ranked as
second commonest malignancy in their study.
The third commonest malignancy was squamous cell car-
cinoma accounting for 15.22% overall. This was different
when compared to reports from both other African stud-
ies and the rest of the world that report squamous cell car-
cinoma as the most frequent malignancy. [1-3,14]
However, it should be noted that the differences in inclu-
sion criteria, clinical practices make it impossible to objec-
tively compare these findings with others. For instance
neither the Asian and American studies report of any case
of Burkitt's lymphoma nor does the Jordanian study
despite the fact that it was based on children and adoles-
cents. [1,3,23]. The difference between our study and
those from Zimbabwe [2] and Nigeria [14] could be due
to the high number of KS cases that were not included in
those two studies. When we considered only the tumors
in the Nigerian study, squamous cell carcinoma preva-
lence in Tanzania increased to nearly equal levels as those
reported in Nigeria but in Uganda the high number of
Burkkit's lymphoma cases still pulled down the preva-
lence of squamous cell carcinoma. This has been reported
in a different Nigerian study hence giving some credence
to our argument. [28] The gender and age distribution are
shown in tables 2 and 3. The Mean age didn't differ from
that of the individual countries. The modal age group in
both hospitals was 51–60 (p ≥ 0.01). This is in line with
what was expected since squamous cell carcinoma is
known to mainly affect older individuals. However, inter-
estingly in Tanzania males were more affected which is in
line with most parts of the world but in Uganda there was
equal sex distribution. Some studies from other parts of
the world have already noted an increase in oral cancer
incidence among females but stable rates among men.
[28-31]This is attributed to equal exposure to cancer risk
factors between women and men and probably over time
Tanzania will register a similar trend as Uganda in terms
of equal prevalence among women and men. Unfortu-
nately the Kenyan study didn't report on squamous cell
carcinoma to allow comparison. [12]The tongue, floor of
the mouth and buccal surface were the commonest sites
among those specified. The tongue as a site of head and
neck cancer ranked high in Nigeria and the incidence of
lingual squamous cell carcinoma has been reported to be
on the increase in America. [28,32] It's worth noting that
unlike the Nigerian study from Ile Ife where no cancer of
the buccal mucosa was reported, it was the third common-
Hamartoma HAM 4 2 0.32
Papilloma PAP 35 22 3.06
Neurofibroma NEF 10 2 0.65
Schwarnoma SCH 0 2 0.11
Mesenchynoma MSA 0 1 0.05
Calcifying Epithelioma of Malherbe CEM 1 1 0.11
Chodro Syrigoma CHSY 1 0 0.05
Retinoblastoma REBA 0 1 0.05
TOTAL 1298 565
Table 1: Distribution of oralfacial neoplasms in Mulago Uganda (UG) and Muhimbili Tanzania (TZ) (Continued)BMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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Table 2: Gender distribution of the oral facial neoplasms
Abbreviation Females Males Unspecified Total M:F Ratio
UG TZ
AME 73 97 2 172 1.28:1 1.36:1
MYX 15 4 2 21 * 1:2.25
AMEF 4 - - 4 * *
AOT 1 1 - 2 ** *
ODT 1 - - 1 - *
ODF 3 2 - 5 - 1:1.5
MAME 1 - - 1 - *
FIB 79 57 - 136 1:1.32 1:1.53
OF 2 - - 2 - *
CF 6 3 - 9 * 1:2
CHD 1 2 - 3 ** 1:1
OST 1 8 - 9 ** 3:1
OSS 2 5 - 7 1:1 4:1
FIS 4 1 - 5 * **
CHS 2 6 - 8 1:6 *
MYXS - 1 - 1 ** -
RCS - 1 - 1 - **
BUR 252 128 2 382 1.89:1 2.25:1
NHL 5 12 - 17 1.75:1 1:1
HLH 1 - - 1 * -
CPL - 1 - 1 - **
SCCa 126 153 4 283 1:1.01 1.9:1
ACa 9 8 - 17 1:1.25 1:1
UCa 6 13 - 19 2.2:1 -
NPCa 1 - - 1 * -
NKTca - 1 - 1 - **
Vca 1 5 - 6 ** 2:1
BCCa 1 - - 1 - *
ADN 10 8 1 19 1:1 *
PLA 51 41 - 92 1:1.3 1:1.2
MOA 1 - - 1 - *
OCA 3 - - 3 * -
ADCa 15 17 - 32 1:1.2 1:1
ACCa 10 7 2 19 1:1.6 1:1
SGCa 1 2 - 3 1:1 **
MSCa 1 3 - 4 3:1 -
MECa 2 7 - 9 1.5:1 **
CaPLA - - 1 1 - -
HAP 1 3 - 4 ** 1:1
KS 199 208 2 409 1.1:1 1:1
HAS 1 - - 1 - *
GCM 5 1 - 6 1:2.5 -
LEI 1 - - 1 - *
RHS 2 7 - 9 3:1 **
LPH 7 5 - 12 1:1.75 **
LPHS - 1 - 1 - **
LIP 13 15 1 29 1:1.57 4:1
LIS 1 1 - 2 * **BMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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est site in our study. [14] On the other hand a study from
Zimbabwe had similar trends in anatomical sites with
ours. [33] Therefore more research is needed to see if there
are differences in anatomical sites affected by squamous
cell carcinoma across Africa compared to the rest of the
world. Anaplastic carcinoma and undifferentiated/poorly
differentiated carcinoma accounted for 1.88% of all
malignant neoplasms seen. This is similar to what has
been reported by Jones et al. [5]
There was only one case of malignant odontogenic neo-
plasm in these series, which showed the rarity of these
entities.
Salivary gland neoplasia is one of the challenging tumors
when it comes to histological typing. The WHO classifica-
tion is aimed at making it easier for researchers to com-
pare prevalence, however, not all centers have re-
diagnosed the entity in accordance with it. In this study
salivary gland neoplasia accounted for about 9% of both
malignant and benign neoplasms, a figure close to that
reported from Europe. [5] Pleomorphic adenoma domi-
nated this group. The peak frequency was the 3rd decade
with equal gender distribution, however, reports from
Brazil and Italy showed a female preponderance.[5,34-36]
Multi center studies are needed to see if there is real sex
predilection or not. Adenoma was the second commonest
benign salivary gland neoplasm. This entity is not
included in the WHO classification [37] nor is it reported
by Jones et al and Lima et al.[5,35] These could be one of
the other adenomas such as canalicular and monomor-
phic adenoma that were not sub-typed. There is need for
an experienced oral pathologist to review these slides so as
to bring them inline with the WHO classification. Inter-
estingly there was no report of Warthins tumor in our
findings an entity reported by others. [5,35] Since this
entity has been reported else where in Africa [38], we can-
not explain its complete absence in our series and may be
a review of slides could yield a few. Among the malignant
salivary gland neoplasms, adenocarcinoma was the com-
monest which is in line with Jones et al but different from
Lima et al. However it should be noted that Jones et al
reported adenocarcinoma and salivary gland adenocarci-
noma as independent entities yet in our study and that of
Lima SS et al there was no distinction between the two.
This could point to the need for a multi-center study to
reclassify these neoplasms as per WHO standing nomen-
clenture. Of the benign neoplasms recorded in our study,
33% were odontogenic with ameloblatoma accounting
for 84% of this group. This was in agreement with African
and Chinese studies but differed from European and
American studies in which odontomas dominated the
odontogenic neoplasms.[1,2,5-7,11,12,39] In fact only
one case of odontoma was found in this series. The high
frequency of ameloblastoma in our study compared to
Europe and America may as well be due to different clini-
cal practices such as not sending all specimens for
hitopathological evaluation, the inclusion criteria of dif-
ferent studies and the harvest period. Therefore it could be
that odontomas due to their appearance radiologically,
surgically and clinical course are not routinely treated and
if treated are rarely sent for histology. All the demograph-
ics in our study agreed with previous reports.
Among the benign non odontogenic neoplasms including
salivary gland neoplasms, fibromas, pleomorphic ade-
noma and papillomas were the commonest in descending
order. This differs from the report by Jones etal [5] in
which papillomas then pleomorphic adenomas were
ranked as first and second. This is hard to draw conclu-
sions. Both fibromas and papillomas had a slight predi-
lection for females which is in contrast with Jones etal. It
should be noted that the numbers in our study are small
compared to Jones et al hence this could be a chance find-
ing. The site distribution of these neoplasms was varied as
can be seen in table 4. Unfortunately, in the majority of
the lesions, the sites were not specified.
Lipomas were also relatively frequent with the demo-
graphics all being in line with published reports. In our
MEP - 1 - 1 ** -
MEL 4 3 - 7 1:4 **
HAM 2 4 - 6 3:1 1:1
PAP 36 20 1 57 1:1.27 1:1.4
NEF 6 6 - 12 1:1.5 **
SCH 2 - - 2 - *
MSA - 1 - 1 - **
CEM 2 - - 2 * *
CHSY 1 - - 1 * -
REBA - 1 - 1 - **
TOTAL 974 871 18 1863
Table 2: Gender distribution of the oral facial neoplasms (Continued)BMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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Table 3: Combined age distribution of oral facial neoplasms biopsy results l
Dx 0–10 11–20 21–30 31–40 41–50 51–60 61–70 71–80 81–90 91+ US mean Range
AME 2 36 54 33 14 11 3 1 - - 18 30.52 5–75
M Y X 5 451111-- - 3 2 2 . 4 2 6 – 6 4
A M E F1 111----- - - 2 7 . 6 7 1 5 – 3 8
A O T - 1------- - 1 **
O D T - -1------ - - **
O D F - 32------ - - 1 9 . 8 0 1 4 – 2 5
M A M E- --1----- - - **
FIB 18 30 22 22 21 11 11 - - - 1 31.00 0.5–70
OF 2
CF - 3 4 - - 1 - - - - 1 27.00 12–52
CHD - - 1 1 - 1 - - - - - 40.50 30–58
O S T 2 24------ - 1 2 1 . 6 0 8 – 4 1
O S S - 1113---- - 1 3 5 . 2 0 2 0 – 4 5
F I S 1 1-2----- - 1 2 6 . 0 0 6 – 4 0
C H S - 1231---- - 1 3 0 . 7 1 1 4 – 4 9
M Y X S- ---1---- - - **
R C S - 1------- - - **
B U R3 4 1 3 5 2-1---- - 3 7 . 2 1 2 – 4 5
N H L 2 511224-- - - 3 5 . 3 3 1 . 5 – 6 3
H L H - --1----- - - **
C P L - --1----- - - **
SCCa 1 2 18 28 56 78 51 20 4 2 23 * *
A C a 2 13123-2- - 3 5 4 . 5 0 1 8 – 8 0
U C a --245322- - 1 4 9 . 2 2 2 3 – 7 2
N P C a - -1------ - - **
N K T c a- ---1---- - - **
Vca - - 1 1 - 3 - - 1 - - 53.84 22–80
B C C a - ----1--- - - **
A D N 2 372211-- - 1 2 9 . 1 6 3 . 1 – 6 1
P L A 3 1 4 3 0 1 9 9661- - 4 3 2 . 5 8 5 – 7 1
M O A - ---1---- - - **
O C A - 3------- - - 1 9 . 0 0 1 7 – 2 0
A D C a - 2664923- - - 4 6 . 7 8 1 8 – 8 0
A C C a - 3216411- - 1 4 6 . 8 6 2 0 – 6 5
S G C a - ---12--- - - 5 2 . 5 0 4 7 – 6 0
M S C a - 1-21---- - - 3 3 . 0 0 1 4 – 4 8
M E C a - 21122--- - 1 3 7 . 2 2 1 3 – 6 0
C a P L A- -------- - 1 **
H A P 1 2-----1- - - 2 8 . 5 0 7 – 8 0
KS 30 32 176 109 34 11 4 - - - 13 31.78 1.6–68
H A S - -------- - 1 **
G C M 4 -1-1---- - - 1 2 . 9 3 . 0 6 – 4 9
L E I - 1------- - - **
R H S 3 41-1---- - - **
L P H 6 21-1-2-- - - 1 7 . 6 1 0 . 7 – 7 0
L P H S - -1------ - - **
L I P 3 76223--2 - 4 3 3 . 3 0 1 – 8 8
L I S - --1-1--- - - 5 1 . 5 0 3 6 – 6 7
M E P 1 -------- - - **BMC Oral Health 2008, 8:19 http://www.biomedcentral.com/1472-6831/8/19
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study hamartomas were not classified as odontogenic or
non odontogenic yet they are known to occur under both
categories. (40)We included them in the non odontogeinc
neoplasms.
Conclusion
The range of diagnosed neoplasms from our study was
diverse and our results should be of interest to patholo-
gists, oral and maxillofacial surgeons, specialist practi-
tioners and general dental practitioners. The results do not
represent the actual prevalence of oral and maxillofacial
disease within the general population, but simply reflect
the frequency of histologically diagnosed neoplasms at
Mulago and Muhimbili national referral hospitals of
Uganda and Tanzania respectively. This survey has shown
that most diagnoses are malignant in nature and often
require surgical management. However, a large propor-
tion of cases such as odontomas, e.t.c., which are not as
aggressive, could have been under represented because of
their clinical course and the clinical practices at these cent-
ers. The disparities noted between the WHO classification
and our report should hopefully generate interest to
reclassify oro-facial neoplasms across the world to enable
better comparison.
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M E L ---1-121- - 2 6 0 . 6 0 4 0 – 7 2
H A M 2 3----1-- - - 1 8 . 0 0 5 – 7 0
P A P 1 6 1 8 1 1 33-2-- - 4 1 6 . 8 7 . 0 8 – 6 5
NEF 1 5 2 2 - - 2 - - - - 28.70 6–70
S C H - 1------- - 1 **
M S A - 1------- - - **
C E M - -2------ - - **
C H S Y - 1------- - - **
R E B A 1 -------- - - **
TOTAL 448 232 372 251 176 155 95 32 7 2 93
Table 3: Combined age distribution of oral facial neoplasms biopsy results l (Continued)
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